Creating Relevant Content Strategies Aligned with Pharma Buyers' Business Cycles

In our recent webinar, "Unlocking Pharma Buyer Preferences: Essential Insights for 2025 Planning," I had an insightful discussion with Ed McCarthy, CEO of Echelon Performance, about the importance of aligning content strategies with pharma buyers' business cycles. Here's a recap of our conversation on this crucial topic.

Click Here to Watch Webinar Recording

Dario: Ed, our survey highlighted the importance of relevant, timely content for pharma buyers. How has this influenced your content strategy at Echelon Performance?

Ed: Dario, it's been a game-changer for us. When we first started working together, we were creating good content, but it wasn't necessarily aligned with our buyers' business cycles. Once we shifted our approach, we saw a dramatic increase in engagement and, ultimately, conversions.

Dario: Can you walk us through how you approach content planning now?

Ed: Absolutely. We start by mapping out the typical business cycle of our target audience - pharma sales leaders. We consider things like when they're setting annual goals, when they're doing mid-year reviews, when they're planning for the next year, and so on. Then we plan our content to align with these key moments in their cycle.

Dario: That makes a lot of sense. Can you give us an example of how this plays out in practice?

Ed: Sure thing. Right now, for instance, we're in Q4. So we're producing content around "Strategies for a Strong Q4 Push in Pharma Sales" and "Navigating Year-End Pressures." We know our audience is focused on finishing the year strong, so we're providing content that directly addresses those needs.

Dario: And how does this change as you move through the year?

Ed: It evolves with our clients' needs. In Q1, we might focus on "Implementing New Sales Strategies for the Year Ahead." By mid-year, we could be talking about "Conducting Effective Mid-Year Performance Reviews." It's all about anticipating what's on our buyers' minds at any given time.

Dario: That's a smart approach. Have you noticed a difference in how your audience engages with this more timely content?

Ed: Absolutely. We've seen a significant increase in engagement across all our channels. Our LinkedIn posts are getting more likes and shares, our webinars are attracting larger audiences, and we're seeing more inbound inquiries as a result. People are resonating with content that speaks directly to their current challenges and priorities.

Dario: Speaking of channels, how do you decide which types of content to create?

Ed: We try to create a mix of content types to cater to different preferences. We do blog posts for those who like to read, webinars for those who prefer audio-visual content, and infographics for those who want quick, digestible information. We've also started experimenting with short-form video content, which has been well-received.

Dario: How do you ensure that your content is not just timely, but also adds real value?

Ed: That's a great question, Dario. We always strive to go beyond just stating the obvious. We try to provide actionable insights, backed by data or case studies where possible. We also leverage our team's extensive experience in pharma sales to offer unique perspectives that our audience might not find elsewhere.

Dario: Have you found any particular types of content to be especially effective?

Ed: Case studies have been particularly powerful for us. Pharma buyers want to see real-world examples of how strategies have worked for companies similar to theirs. We've also had great success with our "expert roundup" pieces, where we gather insights from multiple industry leaders on a particular topic.

Dario: How do you balance creating timely, cycle-aligned content with evergreen content that remains relevant year-round?

Ed: It's definitely a balancing act, Dario. While we put a lot of focus on timely content, we also maintain a library of evergreen content that addresses perennial issues in pharma sales. This might include topics like "Best Practices for Sales Rep Onboarding" or "Techniques for Effective Remote Selling." We regularly update these pieces to keep them fresh and relevant.

Dario: As we look towards 2025, how do you see content strategies in pharma evolving?

Ed: I think we'll see an even greater emphasis on personalization. With advancements in AI and data analytics, we'll be able to deliver increasingly tailored content to individual buyers based on their specific role, company size, therapeutic area, and stage in the buying cycle. I also think we'll see more interactive content that allows buyers to engage more deeply with the material.

Dario: Any final advice for companies looking to improve their content strategies for pharma buyers?

Ed: I'd say the key is to really know your audience. Understand their challenges, their goals, and their business cycles. Don't just create content for the sake of it - every piece should serve a specific purpose and add real value. And always be open to feedback and willing to adapt your strategy as your audience's needs evolve.

Dario: That's excellent advice, Ed. Thank you for sharing your insights and experiences.

To our readers: If you're looking to refine your content strategy to better align with pharma buyers' business cycles, I'm here to help. Whether it's developing a content calendar that maps to your buyers' key moments, creating more engaging and value-driven content, or optimizing your content distribution strategy, I can work with you to craft an approach that resonates with your target audience.

Don't let your content efforts go to waste on messaging that doesn't align with your buyers' needs. Schedule a 30-minute consultation with me to explore how we can enhance your content strategy to drive more engagement and conversions. Simply message me to book a time that works for you.

Remember, in today's pharma landscape, relevant, timely content isn't just nice to have – it's essential for cutting through the noise and establishing your company as a trusted resource. Let's work together to ensure your content strategy is primed for success in 2025 and beyond.